The Sp1 transcription factor plays an important role in mediating the p53-independent activation of the p21 WAF1 (WAF1) promoter by phorbol 12-myristate13-acetate (PMA) in hematopoietic cells. Using GAL4-Sp1 fusion proteins and a luciferase reporter, PMA is shown to activate the transcriptional activity of Sp1 independent of the WAF1 promoter. This activation does not require the Ser/Thr-rich region of Sp1 and can be mediated by 41 amino acids (152-193) of Sp1 that are important for the interaction with human TAF130. Because transforming growth factor-␤ enhances WAF1 promoter activity through both Sp1 and Smad proteins, the role of Smads in PMA transcriptional activation was examined. PMA addition to hematopoietic cells was found to activate a GAL4/Smad-dependent promoter and the transforming growth factor-␤-responsive promoter, p3TP-lux. Immunofluorescence data demonstrate that PMA addition to hematopoietic cells induces the translocation of Smad3 to the nucleus. However, Smad3 does not stimulate the WAF1 promoter, but rather slightly inhibits the PMAmediated induction of transcription from this upstream region. Additionally, transfection of Smad3 did not enhance the activation of GAL4/Sp1 by PMA. These results demonstrate that, while PMA can activate Smad-mediated transcription, Smad proteins do not appear to play a major role in the PMA induction of the WAF1 promoter.
The p21 protein (WAF1 or CIP1) mediates p53-induced growth arrest by complexing with G 1 cyclin-dependent kinases and inhibiting them from phosphorylating the retinoblastoma protein (1, 2) . Additionally, WAF1 complexes directly with the proliferating cell nuclear antigen, suggesting a role for this protein in the regulation of DNA synthesis. WAF1 may have a direct role in controlling apoptotic cell death as genetic disruption of the WAF1 gene increases the apoptotic response to DNA damage (3) . Increases in WAF1 protein can be seen during skeletal muscle and hematopoietic differentiation (4), suggesting that this protein is important in the terminal cell cycle arrest in the G 0 phase of the cycle. The levels of WAF1 protein are controlled both transcriptionally and post-transcriptionally. After DNA damage of fibroblasts, p53 protein increases and binds to two upstream promoter sites increasing the transcriptional activation of the WAF1 promoter, while in comparison tumor necrosis factor-␣ addition to hematopoietic cells modulates WAF1 levels through posttranslational mechanisms (5, 6) .
In hematopoietic cells that are deleted for p53, PMA 1 induces the transcription of WAF1 in a p53-independent manner. This PMA-mediated transcriptional stimulation is regulated by one of several GC-rich regions adjacent to the TATA box that bind the Sp1 and Sp3 transcription factors (7) . Mutation of this site reduces both basal and PMA-induced transcription. Because transcription of a reporter plasmid containing only Sp1 binding sites and a TATA box was induced by PMA, it was suggested that PMA may regulate Sp1 levels directly. However, analysis of Sp1 binding to DNA by gel mobility shift and DNase I footprint experiments indicated that Sp1 was bound to the WAF1/CIP1 promoter both before and after PMA treatment.
The importance of these Sp1 binding sites to p53-independent transcription of WAF1 is demonstrated by the observations that these sequences are essential for the induction of WAF1 by TGF␤ during normal keratinocyte differentiation (8) and for the induction of WAF1 in colon cancer cells by butyrate (9) , as well as the observation that Sp1 bound to these sites interacts with the progesterone receptor during progesterone induction of WAF1 (10) . Nerve growth factor induces both WAF1 and cyclin D1 gene transcription in PC12 cells by activating the Sp1 transcription factor (11) . Likewise, in osteosarcoma cells, Sp1 plays a role in histone deactylase inhibitor activation of WAF1 transcription (12) . Thus, Sp1 binding to the WAF1 promoter is an essential element in the control of transcription of this gene.
It is possible that the regulation of Sp1 through this diverse set of agents occurs by modulation of the basal transcription machinery or other enhancer-binding transcription-activating proteins. Recently, we have shown that the addition of PMA to hematopoietic cells stimulates the phosphorylation of the amino-terminal tail of TBP, suggesting that direct modulation of TBP by PMA could control transcription (13) . Others (14) have demonstrated that PMA increases an essential protein in the basal transcription complex. Studies of the WAF1 promoter transfected into HepG2 cells demonstrated that overexpression of Smad3 could stimulate promoter activity (15) . Smad3 is phosphorylated by TGF␤-mediated activation of the type I receptor and dimerizes with Smad4 (16); this phosphorylated heterodimer then translocates to the nucleus, where it binds to enhancer elements and activates transcription. A dominantnegative mutant Smad4 inhibits induction of the WAF1 promoter by TGF␤, suggesting that Smad proteins play an important role in modulating the activity of this promoter (17) . In HepG2 cells overexpression of Smad3 also stimulated the activity of a GAL4-Sp1 construct (15) , suggesting an interaction between Sp1 and Smad3 in regulating the WAF1 promoter. Because Smad 3 binds to the p300 co-activator and to the transcription factor c-Jun as well as forming a dimer with Smad4, it was proposed that Smad3 might activate transcription of WAF1 by forming a bridge between p300 and other upstream transcriptional activators (18 -20) .
To evaluate the complex mechanism of transcriptional regulation of the WAF1 promoter, we have used K562 cells that respond to PMA treatment with megakaryocytic differentiation (21) . We find that PMA-induced regulation of Sp1 is mediated by 43 amino acids of Sp1 protein necessary for binding to the TBP-associated factor, human TAF130. This PMA activation is inhibited by E1A, but not by an E1A mutant incapable of binding to p300, suggesting that p300 plays a role in PMAinduced WAF1 transcription. Additionally, in K562 cells PMA activated both GAL4-Smad and p3TP-lux, a TGF␤-responsive promoter. PMA induced the phosphorylation of Smad3 and caused the translocation of Smad3 to the nucleus. However, in K562 cells Smad3 transfection did not increase WAF1 transcription or PMA-induced WAF1 transcription. Additionally, EVI-1, a protein that binds Smad3 and inhibits its activity (22) , had no effect on PMA-induced WAF1 transcription. Taken together, these results suggest that PMA regulation of the WAF1 promoter occurs through core transcription factors, but does not involve the Smad pathway.
MATERIALS AND METHODS
Cell Culture and Transfections-K562 human leukemic cells obtained from ATCC (Rockville, MD) were passaged in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% heat-inactivated bovine calf serum and antibiotics at 37°C in 5% CO 2 . For selection of stably transfected cell lines carrying the pMEP vector, cells were passaged after transfection in media containing 200 g/ml hygromycin B for approximately 3 weeks. For transfection, 20 million K562 cells were resuspended in 0.8 ml of PBS and transferred to an electroporation cuvette (Bio-Rad). 20 -50 g of plasmid DNA was added, and the cells were pulsed two times at 25 V, 250 microfarads. The cells were then divided into aliquots and allowed to recover for 5-6 h in the incubator. Cells were then treated with CdSO 4, PMA, or other reagents as indicated. PMA was obtained from Calbiochem. When using TGF␤-neutralizing antibodies (R&D systems), transfected cells were pretreated for 1 h with antibodies before addition of PMA or TGF␤.
Plasmids-The GAL4-Smad3 construct, a gift from Y. Zhang and R. Derynck, was transferred from pSG424 to pBluescript SK using flanking HindIII and XbaI sites, and then into pMEP using KpnI and NotI sites. To make GAL4-Smad3A, a BglII/NotI fragment from the Smad3A expression vector (a gift from X. Liu and H. Lodish) containing COOHterminal coding sequence and three serine to alanine mutations was used to replace the equivalent sequence in wild-type GAL4-Smad3. To make GAL4-Sp1 fusions, PCR primers were designed to amplify the appropriate regions of Sp1 using a full-length Sp1 cDNA as template. The PCR primers were designed with a BamHI site on 5Ј primers and an XbaI site on 3Ј primers to allow cloning of PCR products into pSG424, which contains the GAL4 DNA binding domain (amino acids 1-147), and giving in-frame fusions between GAL4 and Sp1. The sequences encoding the GAL4-Sp1 fusions were cloned into pBluescript (Stratagene) using HindIII and XbaI sites, and then cloned into pMEP using KpnI and NotI sites. GAL4 luciferase reporter plasmids were a gift from A. Patterson and J. Kudlow.
Western Blots-Cell pellets were lysed in 0.5% Nonidet P-40, 50 mM Tris, pH 7.5, 150 mM NaCl, 20 mM EDTA, 20 mM NaF, 1 mM vanadate, 10 mM benzamide, 40 mM glycerol phosphate, and protease inhibitors for 30 min at 4°C. Debris was removed by spinning for 10 min in a microcentrifuge at 4°C. Equal amounts of cell lysate were run on SDS-polyacrylamide gels and transfered to nitrocellulose. After blocking in 10 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20, and 5% bovine serum albumin, the filter was incubated in blocking solution plus anti-GAL4 antibodies (Upstate Biotechnology, Inc.) for 2-4 h. The filter was washed in Tris-buffered saline plus 0.5% Nonidet P-40 for 30 min, then incubated with anti-rabbit horseradish peroxidase antibodies (Amersham Pharmacia Biotech). After further washing, antibody bound to the filter was visualized using ECL detection reagents (Amersham Pharmacia Biotech).
Luciferase Assays-For luciferase assays, cells were lysed for 10 min at room temperature in 25 mM Tris-phosphate, pH 7.8, 2 mM dithiothreitol, 2 mM trans-1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid, 10% glycerol, and 1% Triton X-100. After a 30-s spin in a microcentrifuge to remove debris, equal amounts of protein were brough to a final sample volume of 100 l. Just prior to measurement of light intensity, 100 l of luciferin buffer was added to each sample. The luciferin buffer contained 20 PMA was added at various times before the cells were lysed in the buffer described under "Western Blots." 1 g of anti-FLAG antibody (Sigma M2 monoclonal) bound to 10 l of protein A/G-agarose (Calbiochem) was added to each sample, followed by an overnight incubation on a rocker at 4°C. Immunoprecipitates were then washed three times in lysis buffer, followed by heating at 96°C for 5 min in SDS buffer for SDS-polyacrylamide gel electrophoresis.
Immunofluorescence-K562 cells transfected with FLAG-Smad3 were stained as in Ref. 21 ; briefly, 10 4 cells in PBS plus 1% bovine serum albumin were centrifuged onto glass slides. The cells were then fixed in neutral buffered 10% formalin (Sigma) for 5 min at room temperature and washed three times in PBS. Slides were blocked with PBS containing 1% bovine serum albumin and 0.5% Tween 20 (PBS-TB), incubated 1-4 h at room temperature with 4 g/ml anti-FLAG antibody (Sigma M2 monoclonal) in PBS-TB, washed three times for 5 min at room temperature with PBS-TB, then incubated 1-2 h at room temperature with 3 g/ml anti-mouse IgG-fluorescein isothiocyanate conjugate (Sigma). After three final washes in PBS-TB, coverslips were mounted on the slides with Fluoromount G (Southern Biotechnology Associates). (15) have shown that PMA induction of the WAF1 promoter is mediated through Sp1 binding sites, but the mechanism by which Sp1 regulates PMAinduced transcriptional activation remains unclear. The Sp1 transcription factor contains A and B activation domains and within each domain there are Ser/Thr-and glutamine-rich regions (23) . Since PMA regulates the activity of a number of transcription factors, e.g. c-Jun, c-Ets, through phosphorylation, one possibility to explain the transcriptional regulation of Sp1 by PMA is an induced modification of the Ser/Thr region of this protein. Alternatively, other portions of the molecule might be essential for this induction and thus point to the mechanism of PMA regulation of Sp1.
RESULTS

Activation of GAL4-Sp1 Fusion Proteins by PMA Is Regulated by p300 -Previous studies
To examine whether specific portions of the Sp1 molecule are necessary for PMA-induced regulation of Sp1, the entire A domain (amino acids 83-232) or portions of that domain were cloned as GAL4 fusions under the control of the metallothionein promoter. This expression vector (pMEP) was chosen because the addition of PMA does not affect the level of expression of this promoter. Thus, K562 cells treated with CdSO 4 alone or CdSO 4 plus PMA contain the same amount of GAL4-Sp1 fusion protein (Fig. 1A) . When GAL4-Sp1 fusion proteins containing either Sp1 domain A or Sp1 domain B were transfected into K562 cells along with a GAL4 driven luciferase reporter; both regions of the protein were identically stimulated by PMA. For simplicity, only the construct containing domain A was used for further experiments. Although the removal of the Ser/Thr region decreases the level of basal transcription, deletion of this domain does not affect the level of activation of GAL4/Sp1 transcription by PMA (Fig. 1B) . 41 amino acids in the glutamine-rich region are sufficient for PMA-induced regulation (Fig. 1B) . These 41 amino acids contain the region of Sp1 shown to interact with the basal transcription factor hTAFII130, a component of the TFIID complex (24) . p300 interacts with TAFs and TBP and forms a bridge between the basal transcription machinery and specific transcription factors (25) . This interaction is inhibited by the E1A pro-
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tein, which binds directly to p300 (26) . The TGF␤ induction of the WAF1 promoter is blocked by the adenovirus protein E1A (27) , and the ability of E1A to block induction is dependent on its ability to bind to the coactivator p300. For this reason, the role of p300 in regulating PMA-induced activation by Sp1 was investigated. The E1A protein was transfected along with the Sp1(152-193)-Gal4 construct and the GAL4/luciferase reporter plasmid into K562 cells and the cells treated with PMA. The presence of E1A blocked the activation of this fusion protein by PMA (Fig. 1C) . In comparison, an E1A protein lacking the p300 binding domain (E1A ) had no inhibitory effect. Identical results were demonstrated using the WAF1 promoter (bases Ϫ154 to ϩ16) containing multiple Sp1 binding sites (data not shown). These results suggest a role for p300 in the PMAinduced regulation of the WAF1 promoter. Possible direct contact between Sp1 (or Sp1-associated proteins) and p300 may be necessary for PMA induction of this promoter.
Activation of Smad3 Signaling by PMA-Since both TGF␤ and PMA activate the WAF1 promoter through Sp1 sites (7, 8) and E1A blocks the stimulatory effects of both of these activators, the possibility that they shared a further common mechanism of action was investigated. Recent studies have suggested that the TGF␤-induced interaction between Sp1 and p300 may be mediated by the Smad3 protein. Smad3 has been shown to bind to p300 (18, 19) , and exogenous Smad3 stimulates both the WAF1 promoter and a GAL4-Sp1 fusion protein in HepG2 cells (15) . These observations led to the proposal that Smad3, when phosphorylated and activated by TGF␤, mediates TGF␤ stimulation of the WAF1 promoter by interacting with both Sp1 and p300. This model would account for the fact that TGF␤ mediates WAF1 promoter induction through Sp1 binding sites, but does not affect the binding of Sp1 to these sites (8) .
If PMA were to activate the Smad signal-transduction pathway, a similar mechanism, in which phosphorylated and activated Smad3 forms a bridge between Sp1 and p300, might explain PMA induction of the WAF1 promoter. To determine whether PMA treatment activates the Smad signal-transduction pathway in K562 cells, the cells were co-transfected with a vector expressing a GAL4-Smad3 fusion protein and a luciferase reporter containing GAL4 DNA binding sites. The GAL4-Smad3 fusion gene was placed in the pMEP expression vector described above. Fig. 2 shows that PMA treatment causes a substantial increase in the transcriptional activity of the GAL4-Smad3 fusion protein. This response is enhanced by cotransfection with a Smad4 expression vector, a protein that dimerizes with Smad3 and enhances its activity, and inhibited by cotransfection with the Evi-1 oncoprotein, a protein that binds to Smad3 and inhibits its activity (data not shown).
Previous studies of Smad3 activation by TGF␤ have demonstrated that three carboxyl-terminal serines on Smad3 are phosphorylated in response to treatment with TGF␤, and that these serines are necessary for Smad3 functions, including transcriptional activation (19, 28) . Mutation of these serines to 
alanines creates a dominant-negative Smad3, which inhibits the Smad pathway response to TGF␤. This inhibition is believed to occur through stable interactions between the dominant-negative Smad and the TGF␤ receptor (28) . When a plasmid expressing a GAL4-Smad3A protein, which contains the three serine to alanine mutations, was transfected into K562 cells, the response to PMA was greatly reduced when compared with the wild-type GAL4-Smad3 fusion protein (Fig. 2) . This result shows that the carboxyl-terminal serines are important for the Smad3 response to PMA.
These results with GAL4-Smad3 fusion proteins provide strong evidence that transcriptional activation by Smad3 is mediated by PMA. To confirm PMA activation of the Smad signal-transduction pathway using a known Smad-regulated promoter, the p3TP-lux reporter plasmid was transfected into K562 cells. The p3TP-lux plasmid promoter consists of three 32-base pair phorbol ester response elements and a 94-base pair sequence from the plasminogen activator inhibitor 1 (PAI-1) gene promoter. p3TP-lux is synergistically induced by overexpression of Smads (29) .
As shown in Fig. 3 , p3TP-lux is strongly stimulated by PMA treatment of K562 cells. In comparison, TGF␤ or activin A treatment of K562 cells induces significantly less p3TP-lux activity (data not shown). Transfection of the wild-type Smad3 greatly enhances the PMA-induced stimulation of the 3TP-lux promoter, whereas the COOH-terminal phosphorylation mutant of Smad3 had no effect. In comparison, the Evi-1 protein, an inhibitor of Smad3, does block PMA induction of p3TP-lux. Taken together, these data suggest that PMA regulates the p3TP-lux promoter at least in part through Smad3.
Blocking the TGF␤ Receptor Does Not Inhibit PMA Regulation of the Smad Pathway-The results shown in Figs. 2 and 3 indicate that PMA regulates Smad-dependent promoters in K562 cells. However, PMA-induced stimulation of these promoters could be occurring through the secretion of TGF␤ or the up-regulation of TGF␤ receptors. Both proteins are known to be up-regulated by PMA in other hematopoietic cells (30) .
To examine the role of the TGF␤ protein in PMA-induced activation of the p3TP-lux construct, K562 cells were pretreated with either anti-TGF␤ antibodies (shown to neutralize TGF␤) or control antibodies, then treated with either PMA or TGF␤. As shown in Fig. 4A , although the addition of TGF␤ to K562 cells had only a small effect on p3TP-lux promoter activity, the neutralizing antibodies inhibit TGF␤ activation of p3TP-lux, while the nonspecific antibodies had no effect. In comparison, the TGF␤ antibodies had no effect on PMA stimulation of the p3TP-lux promoter (Fig. 4B) . To evaluate the role of the TGF␤ receptor in PMA-induced stimulation, K562 cells were transfected with a dominant-negative type 1 receptor missing the Smad 3 binding site (31) and the p3TP-lux promoter construct. As shown in Fig. 5 , the dominant-negative receptor blocked TGF␤ activation of p3TP-lux (Fig. 5A ), but not PMA activation (Fig. 5B) . Therefore, neither secretion of TGF␤ nor modulation of the TGF␤ receptor is required for PMAinduced activation of p3TP-lux promoter, suggesting that PMA may modulate Smad3 directly. (31) suggests that Smad2, which is highly homologous to Smad3, can be activated by the ERK pathway independently of the TGF␤ receptor family. Since PMA regulates the activity of the ERK pathway in K562 cells (21) , the ability of PMA to modify the phosphorylation and (Fig. 6) demonstrates that PMA treatment of these K562 cell lines induces the appearance of a diffuse, higher molecular weight band running just above Smad3 in both wild-type Smad3 and Smad3A cell lines. To verify that this band represents phosphorylated Smad3, these two cell lines were labeled with [
PMA Induces Phosphorylation and Translocation of Smad3 to the Nucleus-Recent work
Smad3 in Phorbol Ester-induced Promoter Expression
32 P]orthophosphate and the experiment repeated. As shown in Fig. 6 , PMA induces similar phosphorylation on both wild-type Smad3 and Smad3A. This result indicates that PMA-induced phosphorylation is occurring at a site(s) other than the carboxyl-terminal serines.
Because Smad2 is phosphorylated in an ERK-dependent manner and PMA regulates ERK in K562 cells, the effect of the MEK kinase inhibitor PD98059 on PMA-induced Smad phosphorylationwasexamined.Thisinhibitorwasaddedto[ 32 P]orthophosphate-labeled K562 cells expressing FLAG-Smad3 prior to PMA stimulation. Immunoprecipitation with the Flag antibody demonstrates that PMA-induced phosphorylation of wild-type and mutant Smad is partially blocked by this inhibitor (Fig.  7A) , suggesting that PMA activates ERKs to phosphorylate Smad3. The observation that PMA activation of Smad3 is associated with ERK-mediated phosphorylation suggests that ERK activity may be necessary for Smad3 transcriptional activation. To determine whether ERK activity is necessary for PMA activation of Smad3 in K562 cells, cells were transfected either with p3TP-lux or with the pMEP-GAL4-Smad3 construct and the GAL-luciferase reporter. Transfected cells were then treated with PMA with or without pretreatment with the MEK kinase inhibitor PD 98059. As shown in Fig. 7B , PD 98059 substantially inhibits the PMA-induced transcriptional activation of both the p3TP-lux promoter and the GAL4-Smad3 fusion protein. This result supports the idea that PMA treatment of K562 cells activates Smad3 transcriptional activity through the ERK pathway.
ERK-induced phosphorylation has been implicated in the movement of Smad2 into the nucleus (31) . To evaluate the subcellular location of Smad3 in K562 cells before and after PMA treatment, immunofluorescence analysis of K562 cells stably transfected with wild-type FLAG-tagged Smad3 was carried out. K562 cells were cytospun onto glass slides, fixed, and incubated with an anti-FLAG antibody, followed by fluorescein isothiocyanate-conjugated secondary antibody. As shown in Fig. 8 , untreated cells expressing FLAG-tagged Smad3 show staining at the outer membrane or cytoplasm, but little nuclear staining. However, after 20 h of PMA treatment, many cells showed very intense nuclear staining while a number showed less intense nuclear staining. This variability may occur because these stably-transfected K562 cells were selected batchwise and not as individual clones; thus, individual cells may 
express different levels of FLAG-tagged Smad3. These results suggest that PMA induces the translocation of Smad3 proteins to the nucleus.
Smads Do Not Play a Major Role in PMA-induced Regulation of the WAF1 Promoter-To determine whether the Smad3 pathway plays a role in PMA-induced stimulation of the WAF1 promoter in K562 cells, the WAF1(Ϫ154/ϩ16)-luciferase reporter construct was cotransfected with various Smad expression vectors. As shown in Fig. 9 , Smad3 does not stimulate this promoter, but rather slightly inhibits the PMA response. In contrast to the results presented above with both the GAL4-Smad construct and the p3TP-lux promoter, transfection of Evi has no effect on the PMA-induced response of the WAF1 promoter. In contrast to the p3TP-lux promoter, activin A (Fig. 9B) or TGF␤ (data not shown) treatment of these cells had no effect on the WAF1 promoter.
PMA regulates the WAF1 promoter through Sp1 binding sites, and stimulates the activity of GAL4/Sp1 constructs. If Smad3 is forming a bridge between Sp1 and p300, Smad3 should enhance the PMA-induced activation of the GAL4/Sp1 construct. However, similar to the WAF1 promoter construct, although somewhat less pronounced, the cotransfection of Smad3 inhibited the PMA-induced activity of this construct (Fig. 10) . In summary, although PMA appears to stimulate the activity of Smad3 signal transduction pathway, Smads do not appear to play a role in the regulation of the WAF1 promoter by PMA. A, the luciferase reporter plasmid containing WAF1 promoter sequence from Ϫ154 to ϩ16 was transfected into K562 cells. The WAF1 reporter plasmid was co-transfected with expression vectors containing Smad3 or Evi-1. Samples were divided and treated with PMA or left untreated as in Fig. 2 . B, cells transfected with the WAF1 promoter (with or without cotransfected Smad3) were treated with 150 ng/ml activin A. nase cascades (32) and direct phosphorylation. Sp1 is phosphorylated as a result of terminal liver differentiation (33) , and casein kinase II phosphorylation appears to regulate Sp1 DNA binding (34) . Our deletion analysis of a GAL4/Sp1 fusion protein demonstrates that a 42-amino acid region of the Sp1 A domain devoid of consensus phosphorylation sites for most serine/threonine kinases is sufficient to mediate PMA-induced GAL4/Sp1 activation. Thus, PMA-mediated phosphorylation is unlikely to control the activation of Sp1 by this agent. This 42-amino acid segment of the Sp1 A domain interacts with the Drosophila TAF110 protein (24) , and in a defined experimental system, the basal transcription factors known as TFIIA through H, TFIID (containing TBP and TAFs, including the human homolog of the Drosophila TAF110), the CRISP complex, and RNA polymerase II, appeared to be sufficient to mediate Sp1-transcriptional activation (35) . Since TBP is phosphorylated during PMA-induced K562 differentiation (13) , it is possible that TBP phosphorylation may play a role in this process. Alternatively, PMA might directly regulate TAFs. Recently, PMA addition has also been shown to increase the level of TIG-1, a member or the CRISP/ARC complex of proteins that has recently been described to activate enhancer driven transcription (14) . Therefore, PMA likely regulates an alternative portion of the transcription machinery to effect Sp1 mediated transcription.
PMA-induced up-regulation of both GAL4/Sp1 and WAF1 promoter activity is inhibited by cotransfection and expression of the E1A protein. E1A inhibition of both keratinocyte and muscle cell differentiation (36, 37) is thought to be mediated by the ability of this protein to bind to the carboxyl-terminal region of p300. E1A blocks the cellular interaction of p300 with both its associated histone acetylase, P/CAF, and multiple transcription factors, including c-Fos, by competing with them for the same binding site on p300 (26) . In contrast to a fulllength E1A molecule, an E1A protein with the p300 binding region deleted (amino acids 2-36) did not effect PMA activation of either GAL4/Sp1 or WAF1 transcription, suggesting that p300 is important for this PMA-mediated transcriptional activation. However, because transient transfection of K562 cells yields very poor expression of p300, we have not been able to directly demonstrate that the E1A-induced inhibition of WAF1 transcription is reversed by p300 overexpression. Also, we have been unable to demonstrate by co-immunoprecipitation that Sp1 binds directly to p300. Thus, it is possible that E1A displaces other transcription factors or TAFs from p300 that are essential for Sp1-mediated transcription.
Because TGF␤-activated Smad proteins bind to p300 and appear to enhance GAL4/Sp1 transcription (15, 18) , it is possible to hypothesize that these proteins form a bridge between Sp1 and p300. To investigate this hypothesis, we have studied the direct regulation of Smad protein function by PMA. The addition of PMA to K562 cells activates transcription mediated by a GAL4/Smad fusion protein and by the p3TP-lux promoter. Interestingly, mutation of the three carboxyl-terminal serines to alanines in Smad3, normally phosphorylated by the TGF␤RI, blocks this PMA-stimulated effect. One study has shown these serines to be essential for interaction with p300 and transcriptional activation by TGF␤ (38) . The Smad/p300 interaction was greatly enhanced by TGF␤ treatment of cells, presumably because phosphorylation of Smad is essential for these proteins to interact. Another study (39) mapped the actual p300 binding site to Smad3 amino acids 199 -38 (serine phosphorylation sites are at amino acids 422, 423, and 425). GST-Smad3 fusion proteins containing Smad3 amino acids 199 -381 bound to p300, but fusion proteins containing fulllength Smad3 did not bind to p300 unless the carboxyl-terminal serines were phosphorylated. These observations led to a model that proposed that phosphorylation of Smad3 leads to a conformational change which exposes the p300 binding site. Still a third study (40) mapped the Smad3 p300 binding site to Smad3 amino acids 381-425, but found that mutation of the carboxyl-terminal serines still allowed for some degree of interaction with p300. The role of TGF␤-induced phosphorylation of Smad3 in regulating the interaction with p300 is unclear. We have shown that PMA induces the phosphorylation of Smads, and that this phosphorylation is not decreased by mutation of the three carboxyl-terminal serines to alanines, suggesting that PMA-induced phosphorylation occurs elsewhere. However, we cannot rule out that a minimal interaction of p300 with the carboxyl terminus of dephosphorylated Smad may be necessary for PMA to regulate transcription of this complex.
Interestingly, PD98059, an inhibitor of the MEK enzyme and therefore of ERK phosphorylation, blocks both PMA-mediated phosphorylation of Smad3 and the activation of GAL4/Smad and the p3TP-lux promoter. Direct Smad phosphorylation by ERKs may be needed for transcriptional activation of these proteins by PMA. Alternatively, other core transcriptional factors whose phosphorylation is controlled by ERKs could be important for regulation of Smad-mediated transcription. For example, the PMA-stimulated induction of TBP phosphorylation is ERK-mediated and blocked by PD98059 (13) . Immunofluorescence microscopy demonstrates that PMA treatment stimulates the translocation Smad3 to the nucleus of K562 cells, thus suggesting that inducing a nuclear location of Smad3 could be the mechanism by which PMA activates Smad transcription. Similarly, hepatocyte growth factor (HGF) stimulates the ERK-mediated phosphorylation of Smad2 and induces the translocation of Smad2 to the nucleus (31). However, unlike PMA, HGF does not stimulate the phosphorylation of a Smad2 protein when the carboxyl-terminal three serines of Smad3 are mutated to alanines (31) . In contrast to the results with HGF, Ras transformation inhibits the TGF␤-induced translocation of Smad3 by inducing the ERK-mediated phosphorylation of the linker region (41) . Because PMA induces differentiation of K562 cells to megakarylocytes, it is not possible to specifically identify PMA-induced phosphorylation alone as the cause for this translocation. It is possible that this event could be associated with other biologic processes that occur during hematopoietic differentiation.
The TGF␤-stimulated promoter p3TP-lux contains three AP-1 sites, which bind members of the c-Jun and c-Fos family, and a portion of the PAI-1 promoter. Using F9 cells that do not contain Jun or Fos, Smad3 has been shown to directly activate AP-1 binding sites (20) . Additionally, Smad3 can enhance the response of both Jun and Fos to TGF␤ (20) . PMA addition to hematopoietic cells strongly induces the transcriptional activity of Jun and Fos family members (42) by both elevating the levels of these proteins and inducing their phosphorylation. However, the observation that Evi-1, a transforming protein that inhibits the activity of Smad3, blocks PMA-induced activation of p3TP-lux suggests that Smad3 is also playing a role in the regulation of this transcriptional stimulation. The PMAinduced activation of the p3TP-lux promoter does not appear to be regulated either by increases in the TGF␤ secretion or the up-regulation of the TGF␤ receptor, since the addition of TGF␤ antibodies to the media or the use of a dominant-negative TGFb receptor does not modify PMA activation of p3TP-lux.
The regulation of Smads by PMA in hematopoetic cells does not appear to play a role in the regulation of the WAF1 promoter in these cells. In contrast to its affect on p3TP-lux, Evi-1 does not inhibit the PMA-induced increase in WAF1 promoter transcription, and the transfection of Smad3, which markedly enhances the PMA-induced stimulation of p3TP-lux, has a slightly inhibitory effect on the WAF1 transcription. In K562 cells, unlike the HepG2 cells (15), it was not possible to demonstrate that Smad3 could enhance the activity of GAL4/Sp1, suggesting that in K562 cells Smads do not form a bridge from Sp1 to p300.
In summary, we have demonstrated that PMA stimulates Sp1-mediated transcription by modulating the interaction of this protein with core transcription factors, including possibly p300 and hTAF130 (dTAF110). Although PMA appears to activate Smad-based transcription and stimulates the phosphorylation and nuclear translocation of Smad3, Smad transcription factors do not appear to play a major role in PMA-induced regulation of the WAF1 promoter. The regulation of Smads by PMA could play an important role in regulating PMA-induced megakaryocyte differentiation.
